Damora Therapeutics (DMRA) Non-Current Assets (2019 - 2026)
Damora Therapeutics (DMRA) posted Non-Current Assets of $42000.0 for Q1 2026, down 59.62% on a QoQ basis from $104000.0 in Q4 2025, and down 90.97% year-over-year from $465000.0 in Q1 2025.
Damora Therapeutics (DMRA) Non-Current Assets (2019 - 2026) Analysis & Trends
Damora Therapeutics' Non-Current Assets history runs 8 years deep, the most recent figure standing at $42000.0 for Q1 2026.
- Quarterly Non-Current Assets fell 90.97% year-over-year to $42000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 65.56% YoY) and the FY2025 annual result came in at $104000.0, down 68.67% from the prior year.
- Non-Current Assets was $42000.0 for Q1 2026 at Damora Therapeutics, down from $104000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $11.9 million in Q1 2022 and bottomed at $42000.0 in Q1 2026.
- A 5-year average of $3.9 million and a median of $2.1 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets slipped 23.32% — and 2026, when it plunged 90.97%.
- Damora Therapeutics' Non-Current Assets stood at $9.3 million in 2022, then plunged by 84.36% to $1.5 million in 2023, then plunged by 77.15% to $332000.0 in 2024, then slumped by 68.67% to $104000.0 in 2025, then sank by 59.62% to $42000.0 in 2026.
- Business Quant data shows DMRA's Non-Current Assets at $42000.0 in Q1 2026, $104000.0 in Q4 2025, and $936000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | 42,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42,000.00 |
| Dec 31, 2025 | 104,000.00 |
| Sep 30, 2025 | 936,000.00 |
| Jun 30, 2025 | 664,000.00 |
| Mar 31, 2025 | 465,000.00 |
| Dec 31, 2024 | 332,000.00 |
| Sep 30, 2024 | 2.18 Mn |
| Jun 30, 2024 | 2.10 Mn |
| Mar 31, 2024 | 1.98 Mn |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Jun 30, 2023 | 3.40 Mn |
| Mar 31, 2023 | 7.53 Mn |
| Dec 31, 2022 | 9.29 Mn |
| Sep 30, 2022 | 10.83 Mn |
| Jun 30, 2022 | 10.66 Mn |
| Mar 31, 2022 | 11.90 Mn |
| Dec 31, 2021 | 12.11 Mn |
| Sep 30, 2021 | 28.87 Mn |
| Jun 30, 2021 | 39.11 Mn |